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Research in context 
 
Evidence before this study 
We searched PubMed on April 12, 2016 for the terms “ivacaftor” or “VX-770”, 
“lumacaftor” or “VX-809”, and “clinical trial” with no restrictions on publication date or 
language and retrieved three relevant clinical studies. In Phase 2 studies, combination 
lumacaftor/ivacaftor therapy, but not monotherapy, improved lung function and had an 
acceptable side-effect profile in patients with cystic fibrosis (CF) homozygous for the 
Phe508del CFTR mutation. The Phase 3 TRAFFIC and TRANSPORT studies 
demonstrated a clinically meaningful benefit of lumacaftor/ivacaftor combination therapy 
in this population. To be eligible for these studies patients had to have a screening 
percent predicted forced expiratory volume 1 second (ppFEV1) of 40 to 90. Therefore, 
few data are available on which to base treatment decisions in patients whose ppFEV1 
is below 40.  
 
Added value of this study 
We evaluated the response to lumacaftor/ivacaftor therapy in the Phase 3 TRAFFIC 
and TRANSPORT studies among patients with CF homozygous for the Phe508del 
CFTR mutation stratified by specific categories of lung function, including a subgroup of 
patients with severe lung dysfunction whose ppFEV1 declined to below 40 percentage 
points between screening and baseline. This provided an opportunity to assess the 
response in this group of patients that is often not studied. Results of this prespecified 
subgroup analysis provide evidence that lumacaftor/ivacaftor therapy improved ppFEV1 
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levels in patients across a spectrum of pretreatment lung function. The incidence of 
some respiratory adverse events (AEs) was higher among patients with baseline 
ppFEV1 <40 than those with baseline ppFEV1 ≥40. Across lung function subgroups, 
some respiratory AEs occurred more frequently in patients who received 
lumacaftor/ivacaftor therapy than placebo. These respiratory AEs were associated with 
the initiation of treatment, irrespective of lung function subgroup, and usually resolved 
with continued treatment. Discontinuations due to AEs were low and similar across 
subgroups. 
 
Implications of all the available evidence 
These data demonstrate that lumacaftor/ivacaftor combination therapy benefits patients 
with CF homozygous for the Phe508del CFTR mutation with varying degrees of lung 
function impairment, including those with moderate to severe dysfunction. Prospective 
evaluation is warranted in patients with ppFEV1 values below 40, in particular among 
those with ppFEV1 values below 30, in whom the safety and efficacy of 
lumacaftor/ivacaftor combination therapy are currently being evaluated. 
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Summary  
Background Lumacaftor/ivacaftor combination therapy demonstrated clinical benefits in 
patients with cystic fibrosis homozygous for the Phe508del CFTR mutation. 
Pretreatment lung function is a confounding factor that potentially impacts the efficacy 
and safety of lumacaftor/ivacaftor therapy. 
 
Methods Two multinational, randomised, double-blind, placebo-controlled, parallel-
group Phase 3 studies randomised patients to receive placebo or lumacaftor (600 mg 
once daily [qd] or 400 mg every 12 hours [q12h]) in combination with ivacaftor (250 mg 
q12h) for 24 weeks. Prespecified analyses of pooled efficacy and safety data by lung 
function, as measured by percent predicted forced expiratory volume in 1 second 
(ppFEV1), were performed for patients with baseline ppFEV1 <40 (n=81) and ≥40 
(n=1016) and screening ppFEV1 <70 (n=730) and ≥70 (n=342). These studies were 
registered with ClinicalTrials.gov (NCT01807923 and NCT01807949). 
 
Findings The studies were conducted from April 2013 through April 2014. 
Improvements in the primary endpoint, absolute change from baseline at week 24 in 
ppFEV1, were observed with both lumacaftor/ivacaftor doses in the subgroup with 
baseline ppFEV1 <40 (least-squares mean difference versus placebo was 3∙7 and 3.3 
percentage points for lumacaftor 600 mg qd/ivacaftor 250 mg q12h and lumacaftor 400 
mg q12h/ivacaftor 250 mg q12h, respectively [p<0∙05] and in the subgroup with baseline 
ppFEV1 ≥40 (3∙3 and 2∙8 percentage points, respectively [p<0∙001]). Similar absolute 
improvements versus placebo in ppFEV1 were observed in subgroups with screening 
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ppFEV1 <70 (3∙3 and 3∙3 percentage points for lumacaftor 600 mg qd/ivacaftor 250 mg 
q12h and lumacaftor 400 mg q12h/ivacaftor 250 mg q12h, respectively [p<0∙001]) and 
≥70 (3∙3 and 1∙9 percentage points, respectively [p=0.002] and [p=0∙079]). Increases in 
BMI and reduction in number of pulmonary exacerbation events were observed in both 
LUM/IVA dose groups vs placebo across all lung function subgroups. Treatment was 
generally well tolerated, although the incidence of some respiratory adverse events was 
higher with active treatment than with placebo. 
 
Interpretation Lumacaftor/ivacaftor combination therapy benefits patients homozygous 
for Phe508del CFTR who have varying degrees of lung function impairment. 
 
Funding Vertex Pharmaceuticals Incorporated. 
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Introduction 
 
The most common cystic fibrosis (CF)-causing mutation, Phe508del CF transmembrane 
conductance regulator (CFTR), leads to a variety of defects, including reduced folding 
and trafficking of the CFTR protein to the epithelial cell surface and defective channel 
gating, among others.1–4 Therefore, restoring the chloride transport activity of the 
Phe508del CFTR channel is complex. Lumacaftor (LUM) is a CFTR corrector, which 
selectively increases the processing and trafficking of Phe508del CFTR to the cell 
surface and enhances CFTR–mediated chloride transport in vitro.5 Ivacaftor (IVA) is a 
CFTR potentiator, which facilitates chloride transport by increasing the channel-open 
probability of CFTR on the cell surface.6 Monotherapy with either LUM or IVA was not 
shown to be clinically beneficial in patients with CF homozygous for the Phe508del 
CFTR mutation.7,8 In contrast, clinically meaningful benefits were observed with 
combination therapy in patients with CF homozygous for the Phe508del CFTR mutation 
in a Phase 29 and in two Phase 3, randomised, double-blind, placebo-controlled studies, 
TRAFFIC and TRANSPORT.10  
 
Significant improvements in lung function were observed with LUM 600 mg once daily 
(qd)/IVA 250 mg every 12 hours (q12h) and LUM 400 mg q12h/IVA 250 mg q12h in the 
TRAFFIC and TRANSPORT studies; the mean absolute change in percent predicted 
forced expiratory volume in 1 second (ppFEV1) at week 24 versus placebo ranged from 
2∙8 to 3∙3 percentage points in the pooled analysis (p<0∙001).10 Improvements were 
also observed in nutritional status and rate of pulmonary exacerbations (PEx). These 
data supported the approval of LUM/IVA combination therapy (Orkambi; Vertex 
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Pharmaceuticals Incorporated; Boston, MA, USA) in patients aged 12 and older with CF 
homozygous for the Phe508del CFTR mutation in the United States, the European 
Union, and Canada. 
 
Patients with CF whose ppFEV1 is in the severe range have a greater burden of disease 
associated with a higher rate of PEx and worse nutritional status.11,12 The safety and 
efficacy of new treatments in patients with severe lung dysfunction may not be the same 
as in patients with milder dysfunction. The TRAFFIC and TRANSPORT studies enrolled 
patients with ppFEV1 values of 40 to 90 percentage points at screening, reflecting a 
range of lung function impairment from mild (ppFEV1 ≥70 to ≤90) to moderate (ppFEV1 
40 to 69). Some patients had a ppFEV1 value that decreased to below 40 between 
screening and baseline, providing an opportunity to assess treatment response in this 
clinically important subgroup.10 Prospective evaluation of the safety and efficacy of 
LUM/IVA in patients with severe lung dysfunction is ongoing. Here, we describe a 
prespecified pooled analysis of data from the TRAFFIC and TRANSPORT studies 
performed to determine the efficacy and safety of LUM/IVA combination therapy in 
patients with CF homozygous for the Phe508del CFTR mutation, defined by specific 
categories of lung function, including those with severe lung dysfunction (ppFEV1 <40 at 
baseline).  
 
Methods 
Study design and patients 
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The TRAFFIC and TRANSPORT trials were multinational, randomised, double-blind, 
placebo-controlled, parallel-group, 24-week Phase 3 studies conducted from April 2013 
through April 2014. Both studies were conducted in accordance with the principles of 
the Declaration of Helsinki and in compliance with Good Clinical Practice guidelines and 
all applicable local and national regulations. The study protocol was approved by ethics 
committees, and all patients provided written informed consent.  
 
The design of these nearly identical studies has been described previously and is briefly 
reviewed in the supplemental appendix.10 The studies included patients aged 12 years 
or older with a confirmed diagnosis of CF, homozygous for the Phe508del CFTR 
mutation, and a ppFEV1 of 40 to 90 at the time of screening. Some patients had ppFEV1 
levels that decreased to below 40 between the screening and baseline visits (≤4 
weeks). In the pooled analysis, data from the two studies were pooled by dosing 
regimens. 
 
Outcomes 
For the pooled TRAFFIC and TRANSPORT study data, preplanned subgroup analyses 
of ppFEV1 <40 versus ≥40 at baseline and ppFEV1 <70 versus ≥70 at screening were 
performed for the primary endpoint and key secondary endpoints in a manner similar to 
that reported previously for the entire study cohort.10 The primary endpoint was the 
absolute change from baseline in ppFEV1 at week 24, calculated by averaging the 
mean absolute change at week 16 and the mean absolute change at week 24. Key 
secondary endpoints were: the relative change from baseline in ppFEV1 at week 24 
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(calculated by averaging the mean values for weeks 16 and 24); the percentage of 
patients with at least a 5% relative increase from baseline in ppFEV1 (response derived 
using average relative change at weeks 16 and 24); the absolute change from baseline 
in body mass index (BMI) at week 24; the absolute change from baseline in the Cystic 
Fibrosis Questionnaire-Revised (CFQ-R) respiratory domain score at week 24; and the 
number of PEx through week 24 (expressed as a rate over 48 weeks). In addition, post 
hoc subgroup analyses were performed for the absolute change from baseline in 
ppFEV1 at each study visit, the percentage of patients with at least a 10% relative 
increase from baseline in ppFEV1 (response derived using average relative change at 
weeks 16 and 24), the number of PEx requiring intravenous (IV) antibiotics, and the 
number of PEx requiring hospitalisation. Safety and tolerability were assessed by 
reports of adverse events (AEs) and by clinical laboratory parameters.  
 
Statistical analyses 
The efficacy population included all patients who were randomised and received at least 
one dose of study drug (full analysis set); patients were analysed according to the study 
group to which they were randomised. Pooled data were analysed for each subgroup 
separately, defined according to ppFEV1 <40 and ≥40 at baseline and ppFEV1 <70 and 
≥70 at screening; these analyses were not powered statistically for efficacy 
comparisons between treatment groups. P values <0∙05 were considered statistically 
significant and were not adjusted for multiple comparisons. The least squares (LS) 
means for the subgroup analysis of the absolute and relative changes from baseline in 
ppFEV1 were calculated using a mixed-effects model for repeated measures (MMRM) 
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that included study, sex, age (<18 vs ≥18 years), treatment, visit, and treatment-by-visit 
interaction. The odds ratio versus placebo for the percentage of patients with at least a 
5% and at least 10% relative increase from baseline in ppFEV1 for each subgroup was 
estimated using the Cochran-Mantel-Haenszel test, stratified by study, baseline age 
(<18 vs ≥18 years), and sex. The LS means for the subgroup analysis of absolute 
change in BMI and CFQ-R respiratory domain were calculated using an MMRM model 
that included study, sex, age, treatment, visit, and treatment-by-visit interaction, plus the 
corresponding baseline as a covariate. The rate ratio of PEx events for each subgroup 
(ie, event rate per year for the treatment group vs that for the placebo group) was 
calculated using a negative binomial regression model that included study, treatment, 
sex, and age, with log(time on study in years) as an offset; 48 weeks was considered equivalent 
to 1 year for the analysis.  
The safety analysis included all patients who received any amount of study drug and 
was based on actual treatment received. Patients who received medication from more 
than one treatment group during the studies were considered to be in the lower dose of 
the active treatment group.  
 
Statistical analyses were performed using Statistical Analysis Software version 9∙2 or 
higher. The studies were registered with ClinicalTrials.gov (NCT01807923 and 
NCT01807949). 
 
Role of the funding source 
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The funder participated in the design of the protocol, performed the statistical analysis, 
and was involved in data interpretation. Medical writing as well as editorial support and 
coordination were provided by the funder. All authors had full access to the study data. 
JSE contributed to data interpretation and manuscript conception, writing and revision, 
and made the final decision to submit for publication. 
 
Results 
Of the 1122 patients who were randomised in the TRAFFIC and TRANSPORT studies, 
1108 received at least one dose of study treatment (3 patients in the placebo group, 4 in 
the LUM 600 mg qd/IVA 250 mg q12h group, and 7 in the LUM 400 mg q12h/IVA 250 
mg q12h group did not receive study drug). Three-hundred and forty two patients 
(30∙9%) had a ppFEV1 of ≥70 at screening, and 730 (65∙9%) had a ppFEV1 of <70 at 
screening. One thousand and sixteen patients (91∙7%) had a ppFEV1 of >40 at 
baseline; 81 (7∙3%) had a ppFEV1 level that decreased to <40 between the screening 
and baseline visits (range: 31∙1-39∙9). In the pooled data, treatment groups were well 
balanced across demographic and baseline characteristics, as reported previously.10 
Characteristics of the subgroups at baseline classified by ppFEV1 <40 versus ≥40 and 
by ppFEV1 <70 versus ≥70 are shown in Table 1. A high percentage of patients in each 
subgroup reported maintenance use of bronchodilators and multiple other CF 
treatments. The majority of patients in each subgroup completed 24 weeks of study 
treatment, including 78 of the 81 patients (96∙3%) with severe lung dysfunction at 
baseline (ppFEV1 <40). With respect to patients who received the LUM 400 mg 
q12h/IVA 250 mg q12h dose, there were 29 in the subgroup with ppFEV1 <40 at 
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baseline, 336 in the subgroup with ppFEV1 ≥40 at baseline, 245 in the subgroup with 
ppFEV1 <70 at screening, and 114 in the subgroup with ppFEV1 ≥70 at screening. 
 
Significant improvements in the primary efficacy endpoint, absolute change from 
baseline in ppFEV1 at week 24, were observed with both doses of LUM/IVA (LUM 600 
mg qd/IVA 250 mg q12h and LUM 400 mg q12h/IVA 250 mg q12h) in the subgroup with 
ppFEV1 <40 at baseline (LS mean difference versus placebo [95% confidence interval 
{CI}] was 3∙7 (0∙5-6∙9) and 3.3 (0∙2-6∙4) percentage points, respectively [p<0∙05]) and in 
the subgroup with ppFEV1 ≥40 at baseline (3∙3 (2∙3-4∙4) and 2∙8 (1∙7-3∙8) percentage 
points, respectively [p<0∙001]) (Table 2). Generally similar results favoring LUM/IVA 
over placebo were observed in subgroups with ppFEV1 <70 and ≥70 at screening, 
although statistical significance was not reached in the ≥70 subgroup receiving LUM 
400 mg q12h/IVA 250 mg q12h (Table 3). The absolute change versus placebo across 
all lung function subgroups ranged from 1∙9-3∙7 percentage points, consistent with 
differences observed in the overall population pooled from the two studies by dosing 
regimen (2∙8-3∙3 percentage points).10 Figure 1 shows the absolute change from 
baseline in ppFEV1 at each study visit throughout 24 weeks of treatment in subgroups 
defined by ppFEV1. Improvements in ppFEV1 were observed as early as day 15 and 
were sustained through week 24 with both LUM/IVA doses in these subgroups. 
 
The differences between LUM/IVA and placebo with respect to relative change from 
baseline at week 24 in ppFEV1 were consistent with results for the absolute change in 
ppFEV1. Relative improvements in ppFEV1 with LUM 600 mg qd/IVA 250 mg q12h and 
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LUM 400 mg q12h/IVA 250 mg q12h versus placebo (95% CI) were 9∙9% (1∙2-18∙5) 
and 9∙1% (0∙7-17∙4), respectively in the subgroup with baseline ppFEV1 <40 (p<0∙05) 
and 5∙3% (3∙5-7∙1) and 4∙5% (2∙7-6∙3), respectively in the subgroup with baseline 
ppFEV1 ≥40 (p<0∙001) (Table 2). Relative improvements in ppFEV1 with both LUM/IVA 
doses versus placebo were also observed in the subgroups with screening ppFEV1 <70 
(6∙0% (3∙7-8∙2) and 5∙9% (3∙6-8∙2), respectively) and ≥70 (4∙4% (1∙5-7∙4) and 2∙5% (-
0∙5-5∙5), respectively); once again, significance was not reached in the ≥70 subgroup 
receiving LUM 400 mg q12h/IVA 250 mg q12h (Table 3). The proportion of patients with 
≥5% and ≥10% average relative increases from baseline at weeks 16 and 24 in ppFEV1 
was significantly higher with both LUM/IVA doses than with placebo in subgroups with 
ppFEV1 ≥40 at baseline (p≤0∙002) and ppFEV1 <70 at screening (p<0∙001) (Figure 2). 
Similar trends favoring LUM/IVA doses were observed in the other subgroups, but 
statistical significance was not reached in most comparisons in the smaller subgroup 
with baseline ppFEV1 <40; significance was achieved for most comparisons in the 
subgroup with screening ppFEV1 ≥70 (Figure 2). 
 
On other clinical parameters, we observed generally consistent improvements across 
subgroups. The absolute change in BMI was statistically significant in most subgroups 
(Tables 2-3). Improvements in the CFQ-R respiratory domain score favoring LUM/IVA 
over placebo were observed in some of the larger subgroups, including those with 
ppFEV1 ≥40 at both LUM/IVA doses (Tables 2-3), although variability on this measure 
was high, particularly in the subgroups with small patient numbers. 
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Treatment with LUM/IVA significantly reduced the number of PEx compared with 
placebo in most ppFEV1 subgroups (Table 4). Additionally, trends toward fewer PEx 
events requiring IV antibiotic therapy and hospitalisations were observed in both 
LUM/IVA dose groups versus placebo across all lung function subgroups (Table 4). 
 
The overall incidence of AEs in both LUM/IVA groups and in the placebo group was 
similar among patients with ppFEV1 <40 and ≥40 at baseline and those with ppFEV1 
<70 and ≥70 at screening (Table 5). Because the incidence of AEs was similar between 
the two LUM/IVA dose groups, the safety data of the two dosing regimens were pooled. 
The most commonly reported AEs across all treatment groups were infective PEx of CF 
and cough. The incidence of certain respiratory AEs was greater in the pooled LUM/IVA 
group than in the placebo group in all subgroups; in patients with baseline ppFEV1 <40, 
these AEs with higher incidence in the pooled LUM/IVA group than in placebo included 
cough (39∙6% vs 25∙0%), dyspnoea (26∙4% vs 14∙3%), and respiration abnormal (the 
Preferred Term for the verbatim term of chest tightness [7∙5% vs 3∙6%]). The incidence 
of dyspnoea and respiration abnormal was also greater in the pooled LUM/IVA group 
than in the placebo group in those with baseline ppFEV1 ≥40 (13∙0% vs 7∙4% and 
10∙0% vs 6∙2%, respectively), as well as in those with screening ppFEV1 <70 and ≥70 
(Table 5). Irrespective of lung function subgroup, respiratory AEs were associated with 
the initiation of treatment and usually resolved with continued treatment. The median 
time (min–max) to onset of the first AE of special interest of respiratory symptoms was 2 
(1-170) days for the pooled LUM/IVA groups (n=738) and 43 (1-172) days for the 
placebo group (n=370). Generally similar results were observed across subgroups, with 
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the exception of a notably shorter time to onset of the first AE of special interest of 
respiratory symptoms among placebo-treated patients in the <40 subgroup. The median 
time (min–max) in the <40 subgroup was 1 (1-155) day for the pooled LUM/IVA groups 
(n=18) and 7 (2-43) days in the placebo group (n=5); in the ≥40 subgroup, the median 
time (min–max) was 2 (1-170) days for the pooled LUM/IVA groups (n=150) and 43 (1-
172) days in the placebo group (n=46) . 
 
With respect to baseline ppFEV1 values, the incidence of dyspnoea was approximately 
two times higher in patients with ppFEV1 <40 versus ≥40 in both the placebo group 
(14∙3% vs 7∙4%) and active treatment group (26∙4% vs 13∙0%), consistent with what 
might be expected for a population of patients with more severe lung dysfunction. The 
incidence of dyspnoea was also increased in patients with screening ppFEV1 <70 
versus ≥70 in both the placebo group (10∙7% vs 2∙8%) and active treatment group 
(17∙0% vs 7∙3%). The incidence of cough was greater in patients with baseline ppFEV1 
<40 versus ≥40 in the LUM/IVA group (39∙6% vs 29∙9%) but lower in the placebo group 
(25∙0% vs 41∙5%). The incidence of cough in patients with screening ppFEV1 <70 
versus ≥70 was generally similar in the both the placebo group (38∙7% vs 43∙1%) and 
LUM/IVA group (31∙4% vs 29∙2%). The proportion of patients who discontinued 
treatment because of AEs was small across all subgroups; such discontinuations 
occurred in 3∙6% of patients (n=1) who received placebo and 0% who received 
LUM/IVA in the <40 subgroup, and in 1∙5% of patients (n=5) who received placebo and 
4∙6% of patients (n=31) who received LUM/IVA in the ≥40 subgroup.  
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Discussion 
This pooled analysis of data from the TRAFFIC and TRANSPORT studies shows that 
the efficacy and safety of LUM/IVA in patients with CF homozygous for the Phe508del 
CFTR mutation was similar across lung function subgroups, including ppFEV1 <40 and 
≥40 at baseline and ppFEV1 <70 and ≥70 at screening. 
 
The data in the subgroup with ppFEV1 <40 at baseline were notable given the severity 
of lung function impairment in these patients (ppFEV1 range of 31∙1-39∙9 percentage 
points). In this subgroup, the absolute improvement in lung function, as measured by 
ppFEV1, from baseline at week 24 with both LUM/IVA doses compared with placebo 
ranged from 3∙3 to 3∙7 percentage points, which was similar to the improvement in lung 
function observed in those with ppFEV1 ≥40 (2∙8-3∙3 percentage points) and in the 
overall study population.10 Also notable were outcomes in patients whose ppFEV1 was 
≥70 at screening; lung function improvements in this subgroup were also generally 
consistent with the overall study population.10 
 
Clinical improvements in BMI were also seen with both LUM/IVA doses compared with 
placebo; these were generally similar in magnitude across lung function subgroups. 
Furthermore, clinically meaningful reductions in PEx events were observed across lung 
function subgroups, including those with ppFEV1 <40 at baseline and ≥70 at screening. 
Similarly, reductions in those events requiring the use of IV antibiotics and 
hospitalisation were observed across subgroups; the majority of these comparisons 
reached statistical significance. While the small sample size in some subgroups  limits 
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the strength of our findings, the differences in the main outcome measures    were 
statistically different.and  It is encouragingthat the effect sizes are consistent with 
meaningful clinical benefit in these subgroups.  
 
Using the respiratory domain of the CFQ-R, a CF-specific patient-reported outcome 
instrument,13 significant improvements were noted in some of the subgroups with larger 
patient numbers with consistent trends in other subgroups, with the exception of the  
<40 subgroup treated with the LUM 400 mg q12h/IVA 250 mg q12h dose. A possible 
explanation for this finding could be related to AEs; however, variability on this measure 
was high, particularly in the smaller subgroups, which limited interpretation of these 
findings.  
 
The side-effect profile of LUM/IVA therapy was acceptable in each lung function 
subgroup. The rates of discontinuation due to AEs were low across lung function 
subgroups. The incidence of certain respiratory AEs (such as dyspnoea) was higher in 
subgroups with more impaired lung function (eg, ppFEV1 <40 versus ≥40) in both the 
placebo and LUM/IVA groups. The increased incidence of certain respiratory AEs in 
those with ppFEV1 <40 versus ≥40 is consistent with the nature of CF in a population of 
patients with more severe lung dysfunction. The incidence of certain respiratory AEs 
was also higher in the active treatment groups versus placebo groups, notably in the 
subgroup with ppFEV1 <40 at baseline (eg, dyspnoea and respiration abnormal, or chest 
tightness); when respiratory AEs were present, they were generally associated with the 
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initiation of treatment, irrespective of lung function impairment, and usually resolved with 
continued treatment.  
 
It should be noted that these subgroup analyses were not powered statistically for 
efficacy comparisons between treatment groups. This is particularly important for 
subgroups with small numbers of patients, such as those with ppFEV1 <40 at baseline. 
Nevertheless, the outcomes in patients with severe lung dysfunction were consistent 
with improvements observed in patients with ppFEV1 ≥40 at baseline, suggesting a 
benefit of LUM/IVA combination therapy across a range of differing ppFEV1 values. The 
generalizability of these findings to patients with severe lung dysfunction should be 
approached cautiously, as these trials were not designed to recruit patients with ppFEV1 
levels below 40. Perhaps, these patients may not fully reflect the profile of patients 
specifically recruited based on having ppFEV1 levels <40. Prospective evaluation is 
needed to confirm the benefit of LUM/IVA therapy in this clinically important subgroup. 
Further, we consider the possibility that selection bias may have influenced the patients 
enrolled in the study, in particular in the <40 subgroup, as physicians may have been 
motivated to optimize the health of their patients whose lung function was near the 
eligibility cut off; while this would not be expected to influence efficacy outcomes due to 
the randomised nature of the trial, a potential impact on safety outcomes cannot be 
discounted.  
 
Finally, it is important to bear in mind that the subgroup of patients with severe lung 
dysfunction included in this analysis had ppFEV1 values ranging between 31∙1 to 39∙9 
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percentage points. Special attention may be needed in initiating patients with ppFEV1 
below 30 until further results are available. An open-label Phase 3b trial to assess the 
safety and efficacy of LUM/IVA combination therapy in patients with severe lung 
dysfunction is currently ongoing (ClinicalTrials.gov number, NCT02390219).  
 
In conclusion, the results of these subgroup analyses of the Phase 3 TRAFFIC and 
TRANSPORT studies revealed generally consistent improvements across lung function 
subgroups, including those with ppFEV1 <40 and ≥70, suggesting that LUM/IVA 
combination therapy was generally well tolerated and benefits patients homozygous for 
the Phe508del CFTR mutation across a spectrum of lung function impairment. 
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Characteristics 
Placebo overall 
(n=371) 
LUM/IVA overall 
ppFEV1 <40* 
(n=53) 
ppFEV1 ≥40 
 (n=678) 
ppFEV1 <70 
 (n=527) 
ppFEV1 ≥70 
 (n=204) 
Female, n (%) 181 (48∙8) 31 (58∙5) 331 (48∙8) 269 (51∙0) 93 (45∙6) 
Age, mean (range), years 25∙4 (12-64) 27∙3 (13-44) 24∙7 (12-57) 26∙3 (12-57) 21∙0 (12-53) 
ppFEV1 at baseline, mean (range) 60∙4 (33∙9-99∙8) 37∙2 (31∙1-39∙9) 62∙5 (40∙0-96∙5) 54∙0 (31∙1-69∙8) 77∙9 (70∙0-96∙5) 
Body mass index (mg/kg2),  
mean (range) 
21∙0 (14∙1-32∙2) 20∙9 (16∙1-31∙4) 21∙3 (14∙2-35∙1) 21∙2 (14∙2-35∙1) 21∙4 (14∙6-29∙8) 
Chronic CF therapy use at 
baseline, n (%) 
     
Bronchodilators (any) 342 (92∙2) 50 (94∙3) 631 (93∙1) 496 (94∙1) 185 (90∙7) 
Dornase alfa 281 (75∙7) 41 (77∙4) 517 (76∙3) 407 (77∙2) 151 (74∙0) 
Inhaled antibiotic 258 (69∙5) 33 (62∙3) 421 (62∙1) 351 (66∙6) 103 (50∙5) 
Inhaled hypertonic saline 220 (59∙3) 34 (64∙2) 386 (56∙9) 294 (55∙8) 126 (61∙8) 
Inhaled corticosteroids 220 (59∙3) 35 (66∙0) 386 (56∙9) 311 (59∙0) 110 (53∙9) 
*Eighty-one patients (placebo, n=28; LUM/IVA, n=53) had ppFEV1 that decreased to <40 between screening and baseline. 
CF=cystic fibrosis; IVA=ivacaftor; LUM=lumacaftor; ppFEV1=percent predicted forced expiratory volume in 1 second. 
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Table 1: Patient demographic and baseline characteristics
  
Parameter Placebo 
 
LUM 600 mg qd/IVA 250 mg q12h 
 
LUM 400 mg q12h/IVA 250 mg q12h 
 
ppFEV1 at baseline* 
<40  
(n=28) 
≥40  
(n=338) 
<40  
(n=24) 
≥40  
(n=342) 
<40  
(n=29) 
≥40  
(n=336) 
Absolute change in ppFEV1       
Within group LS mean (SE) 0∙4 (1∙3) -0∙4 (0∙4) – – – – 
LS mean vs placebo (95% CI), 
percentage points† 
– – 3∙7 (0∙5-6∙9) 3∙3 (2∙3-4∙4)           3∙3 (0∙2-6∙4) 2∙8 (1∙7-3∙8) 
 
p value – – 0∙024 <0∙001 0∙036 <0∙001 
Relative change in ppFEV1       
Within group LS mean (SE) 1∙5 (3∙4) -0∙2 (0∙7) – – – – 
LS mean vs placebo (95% CI), %†  – – 9∙9 (1∙2-18∙5)         5∙3 (3∙5-7∙1)          9∙1 (0∙7-17∙4) 4∙5 (2∙7-6∙3)          
p value – – 0∙026 <0∙001 0∙034 <0∙001 
Relative increase of ≥5% from 
baseline in ppFEV1
‡ 
      
Odds ratio vs placebo (95% CI) – – 2∙4 (0∙8-7∙2)     3∙1 (2∙2-4∙3) 1∙7 (0∙6-5∙2) 
 
2∙3 (1∙6-3∙2) 
p value – – 0∙113 <0∙001 0∙331 <0∙001 
Body mass index       
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Within group LS mean (SE) 0∙1 (0∙2) 0∙1 (0∙1) – – – – 
LS mean vs placebo (95% CI), 
kg/m2 
– – 0∙6 (0∙1-1∙2) 0∙3 (0∙1-0∙4)          0∙3 (-0∙2-0∙8) 0∙2 (0∙1-0∙4) 
p value – – 0∙023 <0∙001 0∙261 0∙001 
CFQ-R respiratory domain       
Within group LS mean (SE) 5∙8 (3∙2) 0∙9 (0∙9) – – – – 
LS mean vs placebo (95% CI), 
points 
– – 3∙3 (-5∙2-11∙7) 3∙3 (1∙0-5∙7) -4∙2 (-12∙0-3∙7) 2∙9 (0∙5-5∙3) 
p value – – 0∙446 0∙006 0∙298 0∙017 
*Eighty-one patients had ppFEV1 levels that decreased to <40 between screening and baseline. 
†Assessed by averaging the mean values from weeks 16 and 24, as prespecified in the statistical analysis plan.  
‡Average relative increase from baseline at weeks 16 and 24. 
CFQ-R=Cystic Fibrosis Questionnaire-Revised; CI=confidence interval; IVA=ivacaftor; LUM=lumacaftor; LS=least squares; 
ppFEV1=percent predicted forced expiratory volume in 1 second; SE=standard error; q12h=every 12 hours; qd=every day. 
Table 2: Efficacy results after treatment with LUM/IVA for 24 weeks in patients with ppFEV1 <40 vs ≥40 at baseline   
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Parameter Placebo 
 
LUM 600 mg qd/IVA 250 mg q12h LUM 400 mg q12h/IVA 250 mg q12h 
ppFEV1 at screening* 
<70  
(n=244) 
≥70  
(n=109) 
<70  
(n=241) 
≥70  
(n=119) 
<70  
(n=245) 
≥70  
(n=114) 
Absolute change in ppFEV1       
Within group LS mean (SE) -0∙5 (0∙4) 0∙1 (0∙8) – – – – 
LS mean vs placebo (95% CI), 
percentage points† 
– – 3∙3 (2∙1-4∙4) 3∙3 (1∙3-5∙4) 3∙3 (2∙1-4∙4) 1∙9 (-0∙2-4∙0) 
p value – – <0∙001 0∙002 <0∙001 0∙079 
Relative change in ppFEV1       
Within group LS mean (SE) -0∙3 (0∙9) 0∙7 (1∙1) – – – – 
LS mean vs placebo (95% CI), %†  – – 6∙0 (3∙7-8∙2) 4∙4 (1∙5-7∙4) 5∙9 (3∙6-8∙2) 2∙5 (-0∙5-5∙5) 
p value – – <0∙001 0∙003 <0∙001 0∙103 
Relative increase of ≥5% from 
baseline in ppFEV1
‡ 
      
Odds ratio vs placebo (95% CI) – – 2∙5 (1∙7-3∙7) 3∙8 (2∙1-6∙8) 2∙4 (1∙6-3∙5) 1∙9 (1∙0-3∙4) 
p value – – <0∙001 <0∙001 <0∙001 0∙045 
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Body mass index       
Within group LS mean (SE) 0∙1 (0∙1) 0∙1 (0∙1) – – – – 
LS mean vs placebo (95% CI), 
kg/m2 
– – 0∙2 (0∙0-0∙4) 0∙4 (0∙2-0∙7) 0∙2 (0∙0-0∙3) 0∙3 (0∙1-0∙6) 
p value – – 0∙017 <0∙001 0∙041 0∙006 
CFQ-R respiratory domain       
Within group LS mean (SE) 1∙5 (1∙1) 1∙7 (1∙4) – – – – 
LS mean vs placebo (95% CI), 
points 
– – 4∙1 (1∙3-6∙9) 1∙9 (-1∙9-5∙7) 1∙9 (-0∙9-4∙7) 3∙6 (-0∙3-7∙4) 
p value – – 0∙005 0∙326 0∙184 0∙071 
*Eighty-one patients had ppFEV1 that decreased to <40 between screening and baseline.
  
†Assessed by averaging the mean values from weeks 16 and 24, according to the prespecified statistical analysis plan.  
‡Average relative increase from baseline at weeks 16 and 24. 
CFQ-R=Cystic Fibrosis Questionnaire-Revised; CI=confidence interval; IVA=ivacaftor; LUM=lumacaftor; LS=least squares; 
ppFEV1=percent predicted forced expiratory volume in 1 second; SE=standard error; q12h=every 12 hours; qd=every day. 
Table 3: Efficacy results after treatment with LUM/IVA for 24 weeks in patients with ppFEV1 <70 vs ≥70 at screening   
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Rate ratio vs placebo (95% CI) LUM 600 mg qd/IVA 250 mg q12h LUM 400 mg q12h/IVA 250 mg q12h 
 ppFEV1 at baseline 
 <40 
(n=24)* 
≥40 
(n=342) 
<40 
(n=29)* 
≥40 
(n=336)  
Pulmonary exacerbation events  0∙47 (0∙24-0∙93)    0∙73 (0∙58-0∙92)  0∙59 (0∙33-1∙05)  0∙61 (0∙48-0∙77)  
p value 0∙030 0∙007 0∙074 <0∙001 
Events requiring IV antibiotic therapy  0∙41 (0∙17-0∙98) 0∙57 (0∙43-0∙77) 0∙56 (0∙27-1∙17) 0∙42 (0∙30-0∙58) 
p value 0∙046 <0∙001 0∙122 <0∙001 
Events requiring hospitalisation  0∙43 (0∙14-1∙33)    0∙63 (0∙44-0∙89)    0∙67 (0∙27-1∙65) 0∙36 (0∙23-0∙54)  
p value 0∙142 0∙009 0∙382 <0∙001 
 ppFEV1 at screening 
 <70 
(n=241) 
≥70 
(n=119) 
<70 
(n=245) 
≥70 
(n=114)  
Pulmonary exacerbation events  0∙74 (0∙57-0∙95)    0∙55 (0∙35-0∙85)    0∙65 (0∙50-0∙84)  0∙51 (0∙32-0∙80)  
p value 0∙018 0∙007 0∙001 0∙003 
Events requiring IV antibiotic therapy  0∙53 (0∙39-0∙73)  0∙53 (0∙27-1∙01)    0∙49 (0∙36-0∙68)  0∙22 (0∙09-0∙55) 
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p value <0∙001 0∙052 <0∙001 0∙001 
Events requiring hospitalisation  0∙59 (0∙40-0∙85)  0∙53 (0∙27-1∙06)  0∙48 (0∙32-0∙71) 0∙09 (0∙02-0∙37)  
p value 0∙005 0∙072 <0∙001 0∙001 
*Eighty-one patients had ppFEV1 that decreased to <40 between screening and baseline. 
CI=confidence interval; IV=intravenous; IVA=ivacaftor; LUM=lumacaftor; q12h=every 12 hours; qd=every day. 
Table 4: Pulmonary exacerbation events through week 24 by ppFEV1 subgroup and treatment group   
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Variable, n (%) 
Placebo LUM/IVA* Placebo LUM/IVA* 
ppFEV1 at baseline ppFEV1 at screening 
<40 
(n=28) 
≥40 
(n=337) 
<40 
(n=53) 
≥40 
(n=679) 
<70 
(n=243) 
≥70 
(n=109) 
<70 
(n=487) 
≥70 
(n=233) 
Patients who experienced 
any AE 
 
28 (100) 
 
322 (95∙5) 
 
52 (98∙1) 
 
649 (95∙6) 
 
235 (96∙7) 
 
102 (93∙6) 
 
466 (95∙7) 
 
224 (96∙1) 
AEs reported in ≥10% of 
patients in any subgroup of 
placebo or total LUM/IVA 
        
 Infective PEx of CF 20 (71∙4) 162 (48∙1) 27 (50∙9) 248 (36∙5) 125 (51∙4) 53 (48∙6) 211 (43∙3) 59 (25∙3) 
 Cough 7 (25∙0) 140 (41∙5) 21 (39∙6) 203 (29∙9) 94 (38∙7) 47 (43∙1) 153 (31∙4) 68 (29∙2) 
 Dyspnoea 4 (14∙3) 25 (7∙4) 14 (26∙4) 88 (13∙0) 26 (10∙7) 3 (2∙8) 83 (17∙0) 17 (7∙3) 
 Sputum increased 8 (28∙6) 62 (18∙4) 13 (24∙5) 94 (13∙8) 49 (20∙2) 18 (16∙5) 80 (16∙4) 25 (10∙7) 
 Headache 5 (17∙9) 52 (15∙4) 10 (18∙9) 103 (15∙2) 42 (17∙3) 14 (12∙8) 74 (15∙2) 36 (15∙5) 
 Pyrexia 5 (17∙9) 29 (8∙6) 8 (15∙1) 59 (8∙7) 28 (11∙5) 6 (5∙5) 51 (10∙5) 15 (6∙4) 
 Diarrhoea 2 (7∙1) 29 (8∙6) 7 (13∙2) 73 (10∙8) 19 (7∙8) 10 (9∙2) 62 (12∙7) 16 (6∙9) 
 Nausea 3 (10∙7) 25 (7∙4) 7 (13∙2) 67 (9∙9) 18 (7∙4) 9 (8∙3) 56 (11∙5) 17 (7∙3) 
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 Fatigue 2 (7∙1) 27 (8∙0) 6 (11∙3) 57 (8∙4) 21 (8∙6) 7 (6∙4) 48 (9∙9) 15 (6∙4) 
 Haemoptysis 7 (25∙0) 43 (12∙8) 6 (11∙3) 95 (14∙0) 42 (17∙3) 8 (7∙3) 81 (16∙6) 18 (7∙7) 
 Nasopharyngitis 2 (7∙1) 37 (11∙0) 6 (11∙3) 65 (9∙6) 30 (12∙3) 8 (7∙3) 49 (10∙1) 20 (8∙6) 
 Oropharyngeal pain 1 (3∙6) 29 (8∙6) 6 (11∙3) 61 (9∙0) 17 (7∙0) 11 (10∙1) 43 (8∙8) 24 (10∙3) 
 URTI 0 (0) 19 (5∙6) 6 (11∙3) 53 (7∙8) 12 (4∙9) 5 (4∙6) 39 (8∙0) 18 (7∙7) 
 Nasal congestion 1 (3∙6) 43 (12∙8) 5 (9∙4) 52 (7∙7) 22 (9∙1) 21 (19∙3) 34 (7∙0) 23 (9∙9) 
 Respiration abnormal 1 (3∙6) 21 (6∙2) 4 (7∙5) 68 (10∙0) 19 (7∙8) 2 (1∙8) 49 (10∙1) 22 (9∙4) 
 Blood creatinine 
phosphokinase increased 
 
1 (3∙6) 
 
19 (5∙6) 
 
2 (3∙8) 
 
39 (5∙7) 
 
7 (2∙9) 
 
12 (11∙0) 
 
24 (4∙9) 
 
16 (6∙9) 
 Viral URTI 4 (14∙3) 20 (5∙9) 2 (3∙8) 48 (7∙1) 15 (6∙2) 8 (7∙3) 34 (7∙0) 16 (6∙9) 
*Pooled data for the LUM 600 mg qd/IVA 250 mg q12h and LUM 400 mg q12h/IVA 250 mg q12h groups. 
AE=adverse event; CF=cystic fibrosis; IVA=ivacaftor; LUM=lumacaftor; PEx=pulmonary exacerbation; ppFEV1=percent predicted 
forced expiratory volume in 1 second; URTI=upper respiratory tract infection. 
Table 5: Summary of treatment-emergent adverse events  
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Figure 2 
  
 Figure Legends 
 
Figure 1: Absolute change from baseline in ppFEV1 at each study visit for patients with baseline ppFEV1 <40 (A) or ≥40 
(B), and for patients with screening ppFEV1 <70 (C) or ≥70 (D)  
BL=baseline; CI=confidence interval; IVA=ivacaftor; LUM=lumacaftor; LS=least squares; ppFEV1=percent predicted 
forced expiratory volume in 1 second; q12h=once every 12 hours; qd=once daily. 
 
Figure 2: Percentage of patients with ≥5% and ≥10% average relative increases from baseline in ppFEV1 at weeks 16 
and 24 in patients with ppFEV1 <40 or ≥40 at baseline (A) and ppFEV1 <70 or ≥70 at screening (B)  
IVA=ivacaftor; LUM=lumacaftor; ppFEV1=percent predicted forced expiratory volume in 1 second; q12h=once every 12 
hours; qd=once daily. 
  
37 
 
Supplementary Information 
 
Study design and patients 
The TRAFFIC and TRANSPORT studies were Phase 3, multinational, randomised, double-blind, placebo-controlled, parallel-group studies conducted from 
April 2013 through April 2014.
1
 The study protocols were identical except that ambulatory electrocardiography was measured only in the TRAFFIC study, and 
pharmacokinetic assessments were made in a subgroup of adolescent patients only in the TRANSPORT study.  
Key inclusion criteria were age 12 years or older with a confirmed diagnosis of cystic fibrosis (CF), homozygous for the Phe508del CFTR mutation, a percent 
predicted forced expiratory volume in 1 second (ppFEV1) of 40 to 90 at the time of screening, stable disease, and a willingness to remain on a specified CF 
treatment regimen for 24 weeks. Some patients had ppFEV1 levels that reduced to below 40 between the screening and baseline visits (≤4 weeks). Key exclusion 
criteria were an acute upper or lower respiratory tract infection or change in therapy (including antibiotics) for pulmonary disease occurring within 4 weeks 
before the first dose of study drug, colonization with organisms associated with a more rapid decline in pulmonary status (eg, Burkholderia cenocepacia, 
Burkholderia dolosa, and Mycobacterium abscessus), history of solid organ or haematologic transplantation, or use of strong inhibitors or moderate or strong 
inducers of cytochrome P450 3A within 14 days before the first dose of study drug. 
 
Procedures 
Patients were randomly assigned in a 1:1:1 ratio to treatment with LUM 600 mg qd/IVA 250 mg q12h, LUM 400 mg q12h/IVA 250 mg q12h, or matched 
placebo q12h, stratified by age (<18 vs ≥18 years), sex, and ppFEV1 at screening (<70 vs ≥70). Patients continued to take their prestudy medications throughout 
the study period. The study design schematic is shown in Supplementary Figure 1. Patients initiated study treatment within 4 weeks of screening; clinic visits 
during the 24-week treatment period were scheduled on days 1 (baseline) and 15, and at weeks 4, 8, 16, and 24. Patients who completed all visits during the 
treatment period, regardless of whether or not they discontinued study treatment, were eligible to enrol in a treatment or observational cohort of a rollover 
extension study (PROGRESS; ClinicalTrials.gov number, NCT01931839). A safety follow-up visit was scheduled at 4 weeks after completion of the week 24 
visit but was not required for patients who chose to enrol in the extension study.  
 
 
Supplemental Figure 1: TRAFFIC and TRANSPORT study design
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Supplemental Table 1: Patient demographic and baseline characteristics 
 
Characteristics 
Placebo LUM/IVA overall Placebo LUM/IVA overall 
ppFEV1 <40* 
(n=28) 
ppFEV1 ≥40 
(n=338) 
ppFEV1 <40* 
(n=53) 
ppFEV1 ≥40 
(n=678) 
ppFEV1 <70 
(n=266) 
ppFEV1 ≥70 
(n=100) 
ppFEV1 <70 
(n=527) 
ppFEV1 ≥70 
(n=204) 
Female, n (%) 13 
(46∙4) 
167 
(49∙4) 
31 
(58∙5) 
331 
(48∙8) 
136 
(51∙1) 
44 
(44∙0) 
269 
(51∙0) 
93 
(45∙6) 
Age, mean (range), years 30.3 
(14-55) 
25.0 
(12-64) 
27∙3 
(13-44) 
24∙7 
(12-57) 
26∙9 
(12-64) 
21∙5 
(12-50) 
26∙3 
(12-57) 
21∙0 
(12-53) 
ppFEV1 at baseline, mean 
(range) 
37∙4 
(33∙9-39∙9) 
62.3 
(40∙0-99∙8) 
37∙2 
(31∙1-39∙9) 
62∙5 
(40∙0-96∙5) 
54∙0 
(33∙9-69∙8) 
77∙6 
(70∙0-99∙8) 
54∙0 
(31∙1-69∙8) 
77∙9 
 (70∙0-96∙5) 
Body mass index (mg/kg
2
), 
mean (range) 
20∙3 
(15∙8-25∙0) 
21.1 
(14∙1-32∙2) 
20∙9 
(16∙1-31∙4) 
21∙3 
(14∙2-35∙1) 
20∙9 
(14∙1-30∙8) 
21∙3 
(14∙4-32∙2) 
21∙2 
(14∙2-35∙1) 
21∙4 
(14∙6-29∙8) 
Chronic CF therapy use at 
baseline, n (%) 
        
Bronchodilators (any) 27 (96∙4) 311 (92∙0) 50 (94∙3) 631 (93∙1) 247 (92∙9) 91 (91∙0) 496 (94∙1) 185 (90∙7) 
Dornase alfa 23 (82∙1) 253 (74∙9) 41 (77∙4) 517 (76∙3) 203 (76∙3) 73 (73∙0) 407 (77∙2) 151 (74∙0) 
Inhaled antibiotic 23 (82∙1) 231 (68∙3) 33 (62∙3) 421 (62∙1) 195 (73∙3) 59 (59.0) 351 (66∙6) 103 (50∙5) 
40 
 
Inhaled hypertonic saline 15 (53∙6) 204 (60∙4) 34 (64∙2) 386 (56∙9) 151 (56∙8) 68 (68∙0) 294 (55∙8) 126 (61∙8) 
Inhaled corticosteroids 19 (67∙9) 200 (59∙2) 35 (66∙0) 386 (56∙9) 171 (64∙3) 48 (48∙0) 311 (59∙0) 110 (53∙9) 
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